Journals / Diagnostic and Interventional Radiology / 2018 / Cilt: 24 - Sayı: 6

Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT

Pages
336–341
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT).
📊
Key Findings & Data:METHODS This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18F-FDG PET/CT before any therapy.
💡
Conclusion & Impact:CONCLUSION Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

PURPOSE We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT). METHODS This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18F-FDG PET/CT before any therapy. Patients were divided into subtypes of luminal A, luminal B, ERBB2+, and basal-like based on the immunohistochemistry results. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) before and after correction for lean body mass were achieved and compared. Correlations between metabolic tumor burden and Ki-67 were analyzed and diagnostic performances of volumetric metabolic parameters were evaluated. RESULTS TLG values were significantly different between each molecular subtype, while MTV values were not. Values of TLG were significantly reduced after normalizing for lean body mass in each subtype. Both of them showed correlations with Ki-67 and presented high diagnostic ability in identifying patients with basal-like breast cancer from the rest. TLGs before and after normalizing for the lean body mass had similar diagnostic performances in differentiating patients of basal-like subtype from the rest. CONCLUSION Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.

🔖

Cite This Article

CHEN, W., ZHU, L., YU, X., FU, Q., XU, W., WANG, P. (2018). Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT. Diagnostic and Interventional Radiology, Cilt: 24 - Sayı: 6, 336–341. https://ajindex.com/articles/164874

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011
  2. 1736–1747. [CrossRef] 2. Garcia Vicente AM, Soriano Castrejon A, Leon Martin A, et al. Molecular subtypes of breast cancer: metabolic correlation with (1)(8)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2013
  3. 1304–1311. [CrossRef] 3. Kitajima K, Fukushima K, Miyoshi Y, et al. Association between (1)(8)F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging 2015
  4. 1371–1377. [CrossRef] 4. Wolff AC HM, Hicks DG, Dowsett M, et al. College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014
  5. 241–256. [CrossRef] 5. Burger IA, Huser DM, Burger C, et al. Repeatability of FDG quantification in tumor imaging: averaged SUVs are superior to SUVmax. Nucl Med Biol 2012
  6. 666–670. [CrossRef] 6. Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med 2012
  7. 1041–1047. [CrossRef] 7. Keramida G, Peters AM. Scaling of glomerular filtration rate and SUV for body size: the curious conflict of whole-body metric preferences. J Nucl Med 2016
  8. [CrossRef] 8. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994
  9. 1308–1312. 9. Laffon E, Cazeau AL, Monet A, et al. The effect of renal failure on 18F-FDG uptake: a theoretic assessment. J Nucl Med Technol 2008
  10. 200– 202. [CrossRef] 10. Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008
  11. 1804–1808. [CrossRef] 11. Tahari AK, Chien D, Azadi JR, et al. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 2014
  12. 1481–1484. [CrossRef] 12. Keramida G, Hunter J, Dizdarevic S, Peters AM. The appropriate whole-body index on which to base standardized uptake value in 2-deoxy-2-[(18)F]fludeoxyglucose PET. Br J Radiol 2015
  13. 20140520. [CrossRef] 13. Garcia-Vicente AM, Perez-Beteta J, Perez-Garcia VM, et al. Metabolic tumor burden assessed by dual time